- Asymptomatic HIV-1 infected male patients between the ages of 18 and 55 years
- Patients with CCR5 tropic virus as determined by the Monogram PhenoSense Entry assay.
- Patients who have received any experimental drug within the past four months (prior to
the first dosing day of the study) or who have previously received another CCR5
- Patients with evidence of decompensated liver disease.